Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNP Effect on Thyroid Function in CABG
NCT00636584Phase 4
Key facts
- Status
- Unknown
- Start
- Feb 2008
- Primary completion
- Feb 2008
- Countries
- 1
- Sponsor
- Kavaklıdere Umut Hospital
- Modality
- Small Molecules
- Drugs
- sodium nitroprusside
- Conditions
- coronary artery disease (CAD)
01
Overview
Phase 4, randomised, double-blind trial in coronary artery disease (CAD) comparing Sodium Nitroprusside with Placebo (2 arms). Primary endpoint: Free Triiodothyronine. Status: unknown.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Sodium Nitroprusside
Sodium nitroprusside infusion at 1 mcg/kg/min during rewarming.
Placebo
Saline infusion during rewarming.
03
Who it enrols
Patients undergoing CABG without history of thyroid disease, hypertension, pulmonary disease, peripheral vascular disease, stroke, recent MI, unstable angina, liver/kidney dysfunction, morbid obesity, or cachexia.
04
Endpoints
Primary
Free Triiodothyronine
Secondary
Total Triiodothyronine
Beyond the preview
Go deeper on NCT00636584.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00636584.